Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULMGet Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of NASDAQ:PULM opened at $1.95 on Tuesday. The firm has a market capitalization of $7.12 million, a PE ratio of -0.81 and a beta of 0.94. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.88. The business has a 50-day moving average of $1.93 and a two-hundred day moving average of $1.89.

Pulmatrix (NASDAQ:PULMGet Free Report) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported $0.23 EPS for the quarter. The firm had revenue of $5.89 million for the quarter. Pulmatrix had a negative net margin of 75.73% and a negative return on equity of 44.05%.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

See Also

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.